Skip to main content

AI Can Use ECG Images to Define Risk for Cancer Therapy-Linked Cardiac Dysfunction

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 16, 2024.

via HealthDay

MONDAY, Sept. 16, 2024 -- For patients undergoing treatment for certain types of cancer, artificial intelligence (AI) can use electrocardiographic (ECG) images to define the risk for cardiac dysfunction, according to a study published online Sept. 2 in Circulation: Cardiovascular Quality and Outcomes.

Evangelos K. Oikonomou, M.D., D.Phil., from Yale School of Medicine in New Haven, Connecticut, and colleagues identified 1,550 patients without cardiomyopathy who received anthracyclines and/or trastuzumab for breast cancer or non-Hodgkin lymphoma and had ECG performed 12 months or less before treatment. A validated AI model of left ventricular systolic dysfunction (LVSD) to baseline ECG images was used to define low-, intermediate-, and high-risk groups (AI-ECG LVSD probabilities of <0.01, 0.01 to 0.1, and ≥0.1). The association with early cancer therapeutics-related cardiac dysfunction (CTRCD) or left ventricular ejection fraction (LVEF) <40 percent was explored up to 12 months after treatment.

Of the participants, 5.4, 36.3, and 58.4 percent were classified as high, intermediate, and low risk, respectively, by baseline AI-ECG. The researchers found that the incidence of CTRCD and LVEF <40 percent was higher in association with a high- versus low-risk AI-ECG screen. AI-ECG LVSD probabilities were associated with significantly worse global longitudinal strain among 1,428 temporally linked echocardiograms and ECGs (–19 and –15 percent for <0.1 and ≥0.5, respectively).

"Our findings support the potential utility of AI-ECG monitoring for the cost-effective risk stratification and triage of patients receiving anthracyclines or trastuzumab in the setting of breast cancer or non-Hodgkin lymphoma therapy," the authors write.

Several authors disclosed ties to the biopharmaceutical and health technology industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Moderate-to-Severe TBI Linked to Malignant Brain Tumor Risk

FRIDAY, Sept. 5, 2025 -- A history of moderate-to-severe traumatic brain injury (TBI) is associated with an increased risk for developing malignant brain tumors, according to a...

Housing Assistance Helps Renters With Cancer History

THURSDAY, Sept. 4, 2025 -- Receipt of housing assistance is associated with a lower risk for medical financial hardship among adult renters with a history of cancer, according to...

Risk for Second Cancer Low for Women Treated for Early, Invasive Breast Cancer

THURSDAY, Sept. 4, 2025 -- The risk for second primary cancers is higher for breast cancer survivors than for women in the general population; however, the risk remains low and is...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.